前列腺癌中的缺乏与免疫微环境。
Deficiency and the Immune Microenvironment in Prostate Cancer.
机构信息
Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
出版信息
Clin Cancer Res. 2021 Jan 15;27(2):380-382. doi: 10.1158/1078-0432.CCR-20-3877. Epub 2020 Nov 16.
Abstract
CDK12 inactivation in prostate cancer is associated with tandem genomic duplications that may generate fusion-associated neoantigens and elicit immune responses amenable to checkpoint blockade. In the first study to comprehensively characterize the T-cell immune microenvironment of CDK12-deficient prostate cancers, subsets of immunosuppressive CD4FOXP3 T cells were increased compared with CDK12-proficient controls..
摘要
CDK12 失活与前列腺癌中的串联基因组重复有关，这些重复可能会产生与融合相关的新抗原，并引发可被检查点阻断治疗利用的免疫反应。在第一项全面描述 CDK12 缺陷型前列腺癌中 T 细胞免疫微环境的研究中，与 CDK12 功能正常的对照组相比，抑制性 CD4FOXP3 T 细胞亚群增加。
相似文献
1
Deficiency and the Immune Microenvironment in Prostate Cancer.前列腺癌中的缺乏与免疫微环境。
Clin Cancer Res. 2021 Jan 15;27(2):380-382. doi: 10.1158/1078-0432.CCR-20-3877. Epub 2020 Nov 16.
2
Pan-Cancer Analysis of Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.泛癌症分析功能丧失性改变及其与局灶串联重复表型的关联。
Oncologist. 2019 Dec;24(12):1526-1533. doi: 10.1634/theoncologist.2019-0214. Epub 2019 Jul 10.
3
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.CDK12 失活定义了一类独特的免疫原性晚期前列腺癌。
Cell. 2018 Jun 14;173(7):1770-1782.e14. doi: 10.1016/j.cell.2018.04.034.
4
Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types.CDK12 双等位基因失活肿瘤的预测免疫原性在不同癌症类型中存在差异。
J Mol Diagn. 2021 Dec;23(12):1761-1773. doi: 10.1016/j.jmoldx.2021.08.010. Epub 2021 Sep 22.
5
Characterizing CDK12-Mutated Prostate Cancers.鉴定 CDK12 突变型前列腺癌。
Clin Cancer Res. 2021 Jan 15;27(2):566-574. doi: 10.1158/1078-0432.CCR-20-2371. Epub 2020 Sep 28.
6
Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics.泛癌分析 CDK12 改变鉴定出具有独特基因组和临床特征的前列腺癌亚群。
Eur Urol. 2020 Nov;78(5):671-679. doi: 10.1016/j.eururo.2020.03.024. Epub 2020 Apr 19.
7
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.周期蛋白依赖性激酶 12 突变型晚期前列腺癌的临床结局。
Eur Urol. 2020 Mar;77(3):333-341. doi: 10.1016/j.eururo.2019.09.036. Epub 2019 Oct 20.
8
Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series.描述 CDK12 改变的侵袭性前列腺癌：十二例病例系列。
Int J Clin Oncol. 2022 Dec;27(12):1867-1873. doi: 10.1007/s10147-022-02248-z. Epub 2022 Oct 21.
9
The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer.体细胞突变在前列腺癌肿瘤微环境免疫反应中的作用。
Int J Mol Sci. 2021 Sep 2;22(17):9550. doi: 10.3390/ijms22179550.
10
PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.PTEN 缺陷型前列腺癌与免疫抑制性肿瘤微环境相关，这种微环境是由 IDO1 的表达增加和浸润的 FoxP3+T 调节细胞介导的。
Prostate. 2019 Jun;79(9):969-979. doi: 10.1002/pros.23808. Epub 2019 Apr 18.
引用本文的文献
1
New insights into the dule roles CDK12 in human cancers: Mechanisms and interventions for cancer therapy.CDK12在人类癌症中的双重作用新见解：癌症治疗的机制与干预措施
J Pharm Anal. 2025 Jul;15(7):101173. doi: 10.1016/j.jpha.2024.101173. Epub 2024 Dec 28.
2
Regulatory and memory T lymphocytes infiltrating prostate tumors predict long term clinical outcomes.浸润前列腺肿瘤的调节性和记忆 T 淋巴细胞可预测长期临床结局。
Front Immunol. 2024 Jun 3;15:1372837. doi: 10.3389/fimmu.2024.1372837. eCollection 2024.
3
Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer.杂合性缺失影响CDK12突变型前列腺癌免疫微环境中的MHC表达。
Mol Cytogenet. 2024 May 4;17(1):11. doi: 10.1186/s13039-024-00680-6.
4
Molecular complexity of intraductal carcinoma of the prostate.前列腺导管内癌的分子复杂性。
Cancer Med. 2024 Jan;13(2):e6939. doi: 10.1002/cam4.6939.
5
CDK12 regulates angiogenesis of advanced prostate cancer by IGFBP3.CDK12 通过 IGFBP3 调节晚期前列腺癌的血管生成。
Int J Oncol. 2024 Feb;64(2). doi: 10.3892/ijo.2024.5608. Epub 2024 Jan 8.
6
Prevalence of tumour-infiltrating CD103 cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome.肿瘤浸润 CD103 细胞的患病率可识别出具有不良临床结局的治疗敏感型前列腺癌。
Br J Cancer. 2023 Apr;128(8):1466-1477. doi: 10.1038/s41416-023-02183-4. Epub 2023 Feb 9.
7
Chronological Liquid Biopsy Reveals the Impact of Platinum-Based Chemotherapy on a Prostate Cancer Patient's CDK12 Mutation: A Case Report.时间顺序性液体活检揭示铂类化疗对一名前列腺癌患者CDK12突变的影响：病例报告
Onco Targets Ther. 2022 Sep 2;15:947-952. doi: 10.2147/OTT.S377638. eCollection 2022.
8
Exploring immunotherapy in colorectal cancer.探索结直肠癌的免疫治疗。
J Hematol Oncol. 2022 Jul 16;15(1):95. doi: 10.1186/s13045-022-01294-4.
本文引用的文献
1
Characterizing CDK12-Mutated Prostate Cancers.鉴定 CDK12 突变型前列腺癌。
Clin Cancer Res. 2021 Jan 15;27(2):566-574. doi: 10.1158/1078-0432.CCR-20-2371. Epub 2020 Sep 28.
2
-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.- 前列腺癌改变：标准全身疗法、聚（ADP - 核糖）聚合酶抑制剂和PD - 1抑制剂的临床特征及治疗结果
JCO Precis Oncol. 2020;4:370-381. doi: 10.1200/po.19.00399. Epub 2020 Apr 21.
3
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.转移性前列腺癌的基因组特征和结构变异。
Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19.
4
MSH2 Loss in Primary Prostate Cancer.原发性前列腺癌中 MSH2 的缺失。
Clin Cancer Res. 2017 Nov 15;23(22):6863-6874. doi: 10.1158/1078-0432.CCR-17-0955. Epub 2017 Aug 8.
5
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.全基因组遗传合成致死性分析鉴定 CDK12 为 PARP1/2 抑制剂敏感性的新型决定因素。
Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15.
Zotero 插件